Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Articles

A recent survey covered topics including skin-aging prevention, care-seeking behavior, trust in professionals, and more.

Addressing Disparities in Skin-Aging Prevention Among Women of Color 

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

A cross-sectional study revealed an increase and heightened prevalence of Demodex and demodicosis in individuals with psoriasis receiving biologic therapy.

Biologic Therapy Linked to Increased Density of Demodex Mites and Prevalence of Demodicosis in Patients With Psoriasis vs Controls

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants. 

In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16. 

Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study 

Researchers conducted a population-based study examining a sample of patients with HS during hospital admissions.

Patients With Hidradenitis Suppurativa Have Increased Odds of Respiratory Disease, According to Study Findings

POLL: Which September FDA Approval Were You Most Excited About?